Your browser doesn't support javascript.
Severe COVID-19: NLRP3 Inflammasome Dysregulated.
van den Berg, Daan F; Te Velde, Anje A.
  • van den Berg DF; Amsterdam UMC, Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, Netherlands.
  • Te Velde AA; Amsterdam UMC, Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, Netherlands.
Front Immunol ; 11: 1580, 2020.
Article in English | MEDLINE | ID: covidwho-647056
ABSTRACT
SARS-CoV-2 might directly activate NLRP3 inflammasome resulting in an endogenous adjuvant activity necessary to mount a proper adaptive immune response against the virus. Heterogeneous response of COVID-19 patients could be attributed to differences in not being able to properly downregulate NLRP3 inflammasome activation. This relates to the fitness of the immune system of the individual challenged by the virus. Patients with a reduced immune fitness can demonstrate a dysregulated NLRP3 inflammasome activity resulting in severe COVID-19 with tissue damage and a cytokine storm. We sketch the outlines of five possible scenarios for COVID-19 in medical practice and provide potential treatment options targeting dysregulated endogenous adjuvant activity in severe COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / HMGB1 Protein / Inflammasomes / NLR Family, Pyrin Domain-Containing 3 Protein Limits: Humans Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.01580

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / HMGB1 Protein / Inflammasomes / NLR Family, Pyrin Domain-Containing 3 Protein Limits: Humans Language: English Journal: Front Immunol Year: 2020 Document Type: Article Affiliation country: Fimmu.2020.01580